Inhibitor Report for: Cyanofenphos

Eight pairs of O-methyl and O-ethyl O-(substituted-phenyl) phenylphosphonothionates were evaluated with respect to their delayed neurotoxic activity in hens. O-methyl compounds were in all cases more active than their O-ethyl analogs. The neurotoxic potential of the O-methyl phenylphosphonothionates was 2,5-diCl greater than 4-NO2 greater than 2,4,5-triCl and 2,4,6-triCl greater than 2,4-diCl greater than 2,5-diCl-4-Br greater than 4-CN, when single oral doses were given. Both EPN-ethyl and leptophos-methyl were more neurotoxic in multiple dermal than multiple oral dosing regimens. LD50s for mice and flies were established.

Delayed neurotoxic ataxia, similar to that caused by neurotoxic organophosphorous compounds, has been shown to occur in hens after oral administration of Cyanofenphos (O-ethyl-O-Cyanophenyl phenyl phosphonothionate) following either single or repeated oral doses. Axonal and myelin degeneration affecting the long tracts in spinal cord, peripheral nerves and medulla was demonstrated. The distal fibers with large diameters were particularly affected. This finding is a new contribution which has not been previously recorded. It implies that a thorough study of the structure-activity relationships of phosphonothionates regarding their delayed neurotoxic effect is warranted.

Cyanofenphos (surecide)(R), 25% E.C., O-ethyl O-(4-cyanophenyl) phenylphosphonothioate, was orally administered to one year old lambs at sublethal doses of 1 mg, 2 mg and 4 mg active ingredient kg-1 day-1 for time intervals 60, 45 and 30 days respectively. Irreversible paralytic ataxia symptoms of delayed neuropathy appeared at about 80, 50 and 30 days respectively. In weekly blood samples, AChE (acetylcholine-sterase) and MAO (monoamine oxidase) activities were inhibited depending upon level of dosing and time interval. However no significant correlation was found between the extent of plasma AChE and MAO inhibition and the onset of ataxia symptoms. In brain samples from ataxiated animals, AChE, MAO and NTE (neurotoxic esterase) activities were assayed simultaneously with untreated animal. Direct correlation was shown between in vivo NTE inhibition and the occurrence of delayed neuropathy. Cyanofenphos is the third compound of the phenyl phosphonothioate type on the market showing delayed neuropathy together with Leptophos and EPN.

An equimolal single dose (1 mmole/kg) of leptophos or cyanofenphos was given orally to chickens to assay the clinical and biochemical neurotoxic effects of these two organophosphorus insecticides. Parathion and TOCP at 2 and 1000 mg/kg of chicken body weight were tested in the same manner as negative and positive neurotoxicants, respectively. Three birds of each of five groups tested were sacrificed 1,2,3,7,14,21 and 28 days after treatment and the brains were taken for the biochemical tests. Acetylcholinesterase (AChE) and neurotoxic esterase (NTE) activities were determined in the brain microsomal fractions. In addition, the AChE activity in the brain soluble fractions was measured. Clinical observations indicated that leptophos-, cyanofenphos- and parathion-treated chickens became acutely poisoned but recovered from the typical cholinergic signs in a day or two. However, about 10 to 15 days later leptophos- and cyanofenphos-treated chickens developed the characteristic leg weakness and unrecoverable ataxia seen in birds given TOCP. The biochemical results indicated that cyanofenphos followed by leptophos and parathion produced more in vivo AChE inhibition than that produced by TOCP in both chicken brain soluble and microsomal fractions. Results suggested that there are no correlations between the in vivo effect of TOCP, leptophos and cyanofenphos on AChE and phenyl valerate-total hydrolyzing activities and the ability of these chemicals to produce neuropathy in hens. The results obtained from this study of the in vivo effect of the tested compounds on chicken brain NTE activity present an acceptable correlation between the inhibition of this enzyme and the ability of these chemicals to induce neuropathy. The mechanism and explanation for this correlation are presented. The in vivo effect of the tested compounds on the chicken brain NTE activity was determined using the indirect and a new direct method. The data presented in this report suggested that the new direct technique of assaying NTE activity using 4-nitrophenyl valerate (4-NPV) as substrate, can be useful in the in vivo screening studies of organophosphates for their ability to induce neuropathy in hens.

The susceptibility of wild mallard ducklings to the delayed neurotoxic effect of the neurotoxic organophosphorus insecticides cyanofenphos and leptophos was evaluated following a daily dosing regimen. Ducklings were treated daily with either cyanofenphos or with leptophos at different dose levels for 90 days, or until they died, or became paralyzed. A control group of ducklings given corn oil at 1 ml/kg daily for 90 days was used for comparison. All treated birds were observed daily for any clinical signs of neurotoxicity during the course of this study. All of the surviving ducklings that were treated with cyanofenphos at 4 mg/kg/day or leptophos at 10 mg/kg/day developed clinical signs of delayed neurotoxicity after 7 to 11 weeks of intoxication. Symptoms included leg weakness, ataxia, severe ataxia and paralysis. The observed clinical signs were confirmed by histological changes found in the spinal cords of the treated birds. These changes were of the type associated with organophosphorus-induced delayed neuropathy (OPIDN). These results demonstrate that wild mallard ducklings are susceptible to OPIDN and this avian species can be used in screening organophosphorus compounds for such effect.

Cyanofenphos (Surecide, O-ethyl O-4-cyanophenyl phenylphosphonothioate) is an organophosphorus pesticide. The protective effect against the near lethal dose, 140% the LD50, of formulated cyanofenphos developed in hens pretreated daily with a small dosage of 1.4% the LD50. The oral LD50 for formulated cyanofenphos was 700 mg/kg in the control hens and 1170 mg/kg in the hens pretreated with 10 mg/kg daily for 8 days. The length of the pretreatment period is important in inducing the protective effect. The protective action against 140% the LD50, 1,000 mg/kg, reached its maximum at approximately 24 hr after the last pretreatment. Pretreatment with 20 mg/kg daily for 8 days also acted as an antagonist for a challenge dose of 1,000 mg/kg. Three hours after a challenge dose of 400 mg/kg, brain acetylcholinesterase (AChE) activity was 0.14% delta pH/hr (17.6% of initial value) in hens pretreated with 10 mg/kg daily for 8 days and was 0.21 delta pH/hr (9.1% of initial value) in control hens, the difference being statistically significant (p less than 0.01). The protective effect of pretreatment against the acute toxicity of formulated cyanofenphos appears to be related to the fact that the formulation produced less inhibition of brain AChE activity in the pretreated hens than in the controls.

Eight pairs of O-methyl and O-ethyl O-(substituted-phenyl) phenylphosphonothionates were evaluated with respect to their delayed neurotoxic activity in hens. O-methyl compounds were in all cases more active than their O-ethyl analogs. The neurotoxic potential of the O-methyl phenylphosphonothionates was 2,5-diCl greater than 4-NO2 greater than 2,4,5-triCl and 2,4,6-triCl greater than 2,4-diCl greater than 2,5-diCl-4-Br greater than 4-CN, when single oral doses were given. Both EPN-ethyl and leptophos-methyl were more neurotoxic in multiple dermal than multiple oral dosing regimens. LD50s for mice and flies were established.

Delayed neurotoxic ataxia, similar to that caused by neurotoxic organophosphorous compounds, has been shown to occur in hens after oral administration of Cyanofenphos (O-ethyl-O-Cyanophenyl phenyl phosphonothionate) following either single or repeated oral doses. Axonal and myelin degeneration affecting the long tracts in spinal cord, peripheral nerves and medulla was demonstrated. The distal fibers with large diameters were particularly affected. This finding is a new contribution which has not been previously recorded. It implies that a thorough study of the structure-activity relationships of phosphonothionates regarding their delayed neurotoxic effect is warranted.

Cyanofenphos (surecide)(R), 25% E.C., O-ethyl O-(4-cyanophenyl) phenylphosphonothioate, was orally administered to one year old lambs at sublethal doses of 1 mg, 2 mg and 4 mg active ingredient kg-1 day-1 for time intervals 60, 45 and 30 days respectively. Irreversible paralytic ataxia symptoms of delayed neuropathy appeared at about 80, 50 and 30 days respectively. In weekly blood samples, AChE (acetylcholine-sterase) and MAO (monoamine oxidase) activities were inhibited depending upon level of dosing and time interval. However no significant correlation was found between the extent of plasma AChE and MAO inhibition and the onset of ataxia symptoms. In brain samples from ataxiated animals, AChE, MAO and NTE (neurotoxic esterase) activities were assayed simultaneously with untreated animal. Direct correlation was shown between in vivo NTE inhibition and the occurrence of delayed neuropathy. Cyanofenphos is the third compound of the phenyl phosphonothioate type on the market showing delayed neuropathy together with Leptophos and EPN.